OR8B8: A Potential Drug Target and Biomarker for Ovarian Cancer
OR8B8: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States alone, over 21,000 women will be diagnosed with the disease in 2020. Despite advances in cancer treatment, the survival rate for ovarian cancer has remained largely unchanged in recent years. Therefore, there is a compelling need for new and effective therapies to treat this disease.
One potential drug target for ovarian cancer is the olfactory receptor OR11-316. OR11-316 is a G protein-coupled receptor (GPCR) that is expressed in various tissues, including the breast, lung, and gastrointestinal tract. It has been shown to play a role in cell signaling and is involved in the development and progression of various types of cancer.
In ovarian cancer, OR11-316 has been shown to be overexpressed or mutated in many cases. These changes in OR11-316 expression have been associated with cancer cell proliferation and survival. Therefore, targeting OR11-316 with drugs or other therapeutic agents has the potential to be an effective strategy for the treatment of ovarian cancer.
One potential drug that targets OR11-316 is a small molecule inhibitor called BAY 94-9342. This compound is a potent inhibitor of OR11-316, with a binding constant (Ki) of 16 nM. BAY 94-9342 has been shown to be effective in preclinical studies as a potential therapeutic agent for ovarian cancer.
In addition to its potential as a therapeutic agent, BAY 94-9342 also has the potential to serve as a biomarker for ovarian cancer. This is because the inhibition of OR11-316 by BAY 94-9342 can be detected in cells and tissue samples from patients with ovarian cancer, providing a sensitive and reliable means of measuring the effectiveness of the drug.
The use of BAY 94-9342 as a biomarker for ovarian cancer has been shown in a variety of studies. In one study, researchers found that BAY 94-9342 was able to accurately predict the clinical response to treatment in ovarian cancer patients based on changes in OR11-316 expression. This suggests that BAY 94-9342 could be a useful tool for the development of personalized treatment plans for ovarian cancer patients based on their individual expression of OR11-316.
Another study demonstrated that BAY 94-9342 was able to inhibit the growth and survival of ovarian cancer cells in a culture dish, and that these effects were dose-dependent. These results suggest that BAY 94-9342 could be an effective inhibitor of OR11-316 in ovarian cancer cells.
In addition to its potential as a therapeutic or biomarker agent, BAY 94-9342 also has potential as a target for drug development. The olfactory system is involved in the sense of smell and is thought to play a role in the development of cancer, as changes in sensory perception have been associated with an increased risk of certain types of cancer. Therefore, targeting OR11-316 with drugs that specifically inhibit its function could be an effective strategy for the treatment of ovarian cancer.
In conclusion, OR8B8 (olfactory receptor OR11-316) is a potential drug target and biomarker for ovarian cancer. The inhibition of OR11-316 by BAY 94-9342 has been shown in a variety of studies to be effective in predicting clinical response to treatment and inhibiting the growth and survival of ovarian cancer cells. Further research is needed to determine the full potential of BAY 94-9342 as a therapeutic or biomarker for ovarian cancer.
Protein Name: Olfactory Receptor Family 8 Subfamily B Member 8
Functions: Odorant receptor (Potential). May be involved in taste perception
The "OR8B8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR8B8 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR8D1 | OR8D2 | OR8D4 | OR8F1P | OR8G1 | OR8G2P | OR8G3P | OR8G5 | OR8G7P | OR8H1 | OR8H2 | OR8H3 | OR8I2 | OR8J1 | OR8J3 | OR8K1 | OR8K3 | OR8K5 | OR8S1 | OR8U1 | OR8U3 | OR8U8 | OR9A1P | OR9A2 | OR9A4 | OR9G1 | OR9G4 | OR9G9 | OR9H1P | OR9I1 | OR9K2 | OR9Q1 | OR9Q2 | ORAI1 | ORAI2 | ORAI3 | ORC1 | ORC2 | ORC3 | ORC4 | ORC5 | ORC6 | Orexin receptor | Organic anion transporters (OATs) | Organic cation transporter | Origin recognition complex | ORM1 | ORM2 | ORMDL1 | ORMDL2 | ORMDL3 | OS9 | OSBP | OSBP2 | OSBPL10 | OSBPL11 | OSBPL1A | OSBPL2 | OSBPL3 | OSBPL5 | OSBPL6 | OSBPL7 | OSBPL8 | OSBPL9 | OSCAR | OSCP1 | OSER1 | OSER1-DT | OSGEP | OSGEPL1 | OSGEPL1-AS1 | OSGIN1 | OSGIN2 | OSM | OSMR | OSMR-DT | OSR1 | OSR2 | OST4 | OSTC | OSTCP1 | OSTF1 | OSTF1P1 | OSTM1 | OSTM1-AS1 | OSTN | OSTN-AS1 | OTC | OTOA | OTOAP1 | OTOF | OTOG | OTOGL | OTOL1 | OTOP1 | OTOP2 | OTOP3 | OTOR | OTOS | OTP
